Top-News

Indivior Aktie News

Aktie
WKN:  A3DWFC ISIN:  GB00BN4HT335 US-Symbol:  INDV Branche:  Pharmazeutika Land:  USA
34,97 $
+0,37 $
+1,07%
30,033 € 19:39:28 Uhr
Depot/Watchlist
Marktkapitalisierung *
3,27 Mrd. €
Streubesitz
13,75%
KGV
-
Dividende
0,42 €
Dividendenrendite
1,51%
Index-Zuordnung
-

Indivior News

20.11.25 - PR Newswire
Indivior Concludes Legacy U.S. Department of Justice Matter
Indivior Concludes Legacy U.S. Department of Justice Matter PR Newswire
19.11.25 - PR Newswire
Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference
Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference PR Newswire
03.11.25 - PR Newswire
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
Indivior Presents New Real-​World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine PR Newswire
30.10.25 - PR Newswire
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance PR Newswire
28.10.25 - PR Newswire
Indivior to Participate in the Stifel 2025 Healthcare Conference
Indivior to Participate in the Stifel 2025 Healthcare Conference PR Newswire
16.10.25 - PR Newswire
Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th
Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th PR Newswire
15.10.25 - PR Newswire
Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment
Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment PR Newswire
01.10.25 - PR Newswire
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation PR Newswire
20.08.25 - PR Newswire
Indivior to Participate in Upcoming Investor Events
Indivior to Participate in Upcoming Investor Events PR Newswire
31.07.25 - PR Newswire
Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance
Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance PR Newswire
25.07.25 - PR Newswire
Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained PR Newswire
23.07.25 - PR Newswire
Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder
Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-​Release Buprenorphine, Reduced Odds of Emergency Department Visits for ...
17.07.25 - PR Newswire
Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st
Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st PR Newswire
08.07.25 - PR Newswire
Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs
Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs PR Newswire
30.06.25 - PR Newswire
Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes
Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes PR Newswire
24.06.25 - PR Newswire
Indivior Appoints Tony Kingsley to the Board of Directors
Indivior Appoints Tony Kingsley to the Board of Directors PR Newswire
19.06.25 - PR Newswire
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users PR Newswire
02.06.25 - PR Newswire
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained PR Newswire
27.05.25 - PR Newswire
Indivior Announces Patrick Barry as Chief Commercial Officer
Indivior Announces Patrick Barry as Chief Commercial Officer PR Newswire
13.05.25 - PR Newswire
Indivior to Participate in Upcoming Investor Events
Indivior to Participate in Upcoming Investor Events PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +2,17%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »